Paris based software company, BrightHeart has raised €2 million ($2.1 million) to develop its artificial intelligence (AI) technology for detecting heart conditions in foetuses.
The company’s AI-driven software uses data from 20,000 foetal exams to detect early signs of heart conditions and help clinicians make delivery decisions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The latest funding was secured from European life science venture capital firm, Sofinnova Partners which marks the fourth investment from its medtech acceleration fund, Sofinnova MD Start III.
BrightHeart said the investment will be used to develop the technology, expand the team, and prepare regulatory submissions.
The company has already begun preparation of regulatory submissions for its first product in key geographies and filed patent applications in Europe and the U.S. Following its formation a few months ago BrightHeart is finalising the first adaptation of its software.
The World Health Organization (WHO) estimates that 240,000 new-borns die worldwide every year due to congenital disorders including heart defects with a further 170,000 deaths in children between the ages of one month and five years.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCécile Dupont, BrightHeart’s Chief Executive Officer said the tech has the potential to revolutionise screening for congenital heart defects and allow early interventions to improve the child’s chance of survival. “Prenatal diagnosis of foetal heart defects can significantly improve newborn outcomes, but in practice, as few as 30% are detected,” said Dupont.
In March this year Sofinnova launched its digital medicine strategy to back start-ups developing innovations addressing systemic challenges in healthcare.
